| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1398635 | European Journal of Medicinal Chemistry | 2016 | 12 Pages |
Abstract
•A series of novel tetrahydroisoquinoline-C-aryl glucosides were synthesized.•They were evaluated for the inhibition of human SGLT2.•The structure-activity relationship was discussed.•Compound 13h exhibited equivalent in vitro inhibitory activity with dapagliflozin.
A series of novel tetrahydroisoquinoline-C-aryl glucosides has been synthesized and evaluated for the inhibition of human SGLT2. Compared with dapagliflozin, compound 13h exhibited equivalent in vitro inhibitory activity against SGLT2, which might become a promising candidate for the treatment of type 2 diabetes.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Xuan Pan, Yi Huan, Zhufang Shen, Zhanzhu Liu,